长期使用他汀的老年人停药是否安全?STREAM研究结果
Ditching Primary Prevention Statins in Old Age? Technically 'Safe' With Caveats
STREAM研究显示,长期使用他汀的老年人停药后心血管风险趋势增加,但总体上是安全的。研究未发现生活质量改善,强调了个体化决策的重要性。
研究显示长期使用他汀的老年人停药后心血管风险趋势增加,但总体上是安全的,强调了个体化决策的重要性。
— Uptick in cardiovascular risk did not reach statistical significance in STREAM trial
by Nicole Lou, Senior Staff Writer, MedPage Today
November 8, 2026 • 4 min read
Long-time statin users over age 70 were arguably fine stopping therapy in the STREAM randomized trial, but the results hardly boded well for longer-term cardiovascular safety, and there was no upside in quality of life.
A strategy of discontinuing statins technically met expectations as the trial's primary outcome (a composite of heart attack, ischemic stroke, and death) did not result in a significantly reduced mean event-free survival time over 2 years (96.5 weeks vs 98.5 weeks with statin continuation on intention-to-treat analysis, P<0.001 for non-inferiority).
Nicolas Rodondi, MD, MAS, of Inselspital, University of Bern, Switzerland, concluded that statin discontinuation is "generally safe" in presenting the trial at the American Heart Association (AHA) annual meeting held in Chicago.
"If you have a very sick old patient with a lot of other severe chronic conditions, likely not a long life expectancy, a 2-week difference might not be worse," Rodondi suggested during a press conference. "An older adult, very healthy, with some other chronic condition, but without disease problems in your life, it may be also wise to discuss to continue statins. So it will be really a decision of the patient given this information."
Numerically at least, however, primary endpoint events trended the wrong way for statin discontinuation, reaching 10.7% versus 8.2% with continuation among multimorbid older adults without cardiovascular disease taking statins for primary prevention in STREAM. For every 40 individuals who discontinued statins, there was one additional cardiovascular event over 2 years. Looking at the entirety of the available follow-up, cardiovascular events were also numerically elevated with statin discontinuation (12.7% vs 9.2%) over a median 103 weeks.
Meanwhile, it made no difference in patient-centered secondary outcomes (e.g., pain, falls, sarcopenia) whether patients had stayed on or gotten off their primary prevention statins -- undermining some of the arguments for statin withdrawal in the first place.
"There's lots of reasons why people who are older don't feel good, but it would seem as though stopping statins is not going to be the answer," commented Karen Alexander, MD, of Duke Health in Durham, North Carolina, during the press conference.
STREAM thus reiterates findings from the recent SITE/SAGA trial. That randomized study, notably having fallen short of its planned enrollment, showed no significant increase in mortality after discontinuing statins, albeit no quality of life improvement, either.
Rodondi noted that there were subgroup data in STREAM indicating disproportionately safer outcomes withdrawing statins for people with diabetes and relatively healthy people not recruited from the hospital setting.
"The investigators use the word 'safe,' I might say acceptable risk, but there was at least acceptable risk in deprescribing in the right population, and this is important as we think about shared decision-making with our patients," said session moderator Amit Khera, MD, MSc, of UT Southwestern in Dallas.
"I think that the take-home is that older adults are a heterogeneous group. We know that many primary prevention older adults, in fact, 15 to 18%, have no coronary artery calcium. Many have other competing risks that make continuing statins not logical. So we are back in the individual decision-making within the clinic, and this is a priority-based and context-based decision, and it will continue to be," agreed Alexander.
STREAM was simultaneously published in the New England Journal of Medicine.
The open-label, non-inferiority trial from Europe was conducted from 2021 to 2025 and included people 70 or older with at least two chronic conditions who were taking statins for primary prevention.
Rodondi and colleagues had 1,880 participants randomized to statin discontinuation or continuation. This cohort averaged age 77.5 and was 46.9% women. Nearly one in three had diabetes. Over half had been recruited in the primary care setting as opposed to the hospital.
Baseline LDL cholesterol was 88.9 mg/dL for both study arms, with the existing statin intensity varying from low (7.5%) to moderate (72.9%) to high (19.6%).
A subset of 235 participants had lipids re-measured after 12 months. At that point, LDL cholesterol was 176.0 mg/dL and 99.4 mg/dL between discontinuation and continuation groups, respectively.
"Biologic mechanisms may explain increased cardiovascular risk after statin discontinuation, as discontinuation may accelerate atherosclerosis through endothelial dysfunction and proinflammatory and prothrombotic pathways," study authors wrote.
Serious adverse events occurred in 43.0% of the participants in the discontinuation group and in 39.8% in the continuation group.
The STREAM investigators acknowledged that their study design did not allow for blinding, and there were substantial crossovers during study conduct.
"Although deprescribing inappropriate drugs in older adults appears to be safe, the results of our trial suggest that additional randomized trials of discontinuation are needed for specific drugs; the use of other cardiovascular preventive medications over the period of follow-up should also be assessed, because these cointerventions can bias results," they wrote.
来源:MedPage Today · medpagetoday.com